相似文献
1
Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study.
Blood. 2023 Dec 28;142(26):2327-2331. doi: 10.1182/blood.2023021274.
2
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
Lancet Oncol. 2020 Jul;21(7):978-988. doi: 10.1016/S1470-2045(20)30225-4. Epub 2020 Jun 5.
3
Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison.
Adv Ther. 2022 Jun;39(6):2668-2687. doi: 10.1007/s12325-022-02094-5. Epub 2022 Apr 11.
4
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
Haematologica. 2021 Sep 1;106(9):2417-2426. doi: 10.3324/haematol.2020.275958.
5
Tafasitamab and lenalidomide for relapsed/refractory diffuse large B-cell lymphoma in a patient on chronic intermittent hemodialysis.
J Oncol Pharm Pract. 2023 Jan;29(1):239-241. doi: 10.1177/10781552221102318. Epub 2022 May 18.
6
RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma.
Clin Cancer Res. 2021 Nov 15;27(22):6124-6134. doi: 10.1158/1078-0432.CCR-21-1471. Epub 2021 Aug 25.
7
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.
Ann Hematol. 2023 Jul;102(7):1773-1787. doi: 10.1007/s00277-023-05196-4. Epub 2023 May 12.
8
Clinical Treatment Guidelines for Tafasitamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Oncologist. 2023 Mar 17;28(3):199-207. doi: 10.1093/oncolo/oyac256.
9
Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study.
Clin Cancer Res. 2022 Sep 15;28(18):4003-4017. doi: 10.1158/1078-0432.CCR-21-3648.
10
Treatments for relapsed-refractory diffuse large B-cell lymphoma: comparison of overall survival outcomes observed with four novel agents.
Eur Rev Med Pharmacol Sci. 2022 Jul;26(13):4666-4670. doi: 10.26355/eurrev_202207_29190.
引用本文的文献
1
Sodium 2-Mercaptoethanesulfonate (MESNA), Ifosfamide, Mitoxantrone, and Etoposide (MINE) in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Is the Old Regimen Still Gold?
Cureus. 2025 Jul 1;17(7):e87128. doi: 10.7759/cureus.87128. eCollection 2025 Jul.
2
Molecular Pathways and Targeted Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL).
Cancers (Basel). 2025 Jul 11;17(14):2314. doi: 10.3390/cancers17142314.
3
Copanlisib in combination with rituximab and bendamustine for transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma patients: Results from the phase II multicentre FIL Copa-BR trial from Fondazione Italiana Linfomi (FIL).
Br J Haematol. 2025 Aug;207(2):445-454. doi: 10.1111/bjh.20204. Epub 2025 Jun 10.
4
Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study.
Blood Adv. 2025 Aug 12;9(15):3694-3705. doi: 10.1182/bloodadvances.2024015262.
5
Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma.
Biomark Res. 2025 Jan 23;13(1):18. doi: 10.1186/s40364-024-00706-6.
6
Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centers.
Haematologica. 2025 Mar 1;110(3):706-714. doi: 10.3324/haematol.2024.285977.
7
Tumor Biology Hides Novel Therapeutic Approaches to Diffuse Large B-Cell Lymphoma: A Narrative Review.
Int J Mol Sci. 2024 Oct 23;25(21):11384. doi: 10.3390/ijms252111384.
8
Sequencing of therapy for patients with diffuse large B-cell lymphoma in the era of novel drugs.
Br J Haematol. 2024 Dec;205(6):2163-2174. doi: 10.1111/bjh.19860. Epub 2024 Oct 28.
9
The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas.
Blood Adv. 2024 Sep 10;8(17):4700-4710. doi: 10.1182/bloodadvances.2021004535.
10
Novel Targets and Advanced Therapies in Diffuse Large B Cell Lymphomas.
Cancers (Basel). 2024 Jun 17;16(12):2243. doi: 10.3390/cancers16122243.
本文引用的文献
1
Characteristics and Clinical Outcomes of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Who Received At Least 3 Lines of Therapies.
Clin Lymphoma Myeloma Leuk. 2022 Jun;22(6):373-381. doi: 10.1016/j.clml.2021.11.011. Epub 2021 Nov 22.
2
The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma.
Hemasphere. 2021 Nov 18;5(12):e666. doi: 10.1097/HS9.0000000000000666. eCollection 2021 Dec.
3
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
Haematologica. 2021 Sep 1;106(9):2417-2426. doi: 10.3324/haematol.2020.275958.
4
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
Lancet Oncol. 2020 Jul;21(7):978-988. doi: 10.1016/S1470-2045(20)30225-4. Epub 2020 Jun 5.
5
Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYC.
Leuk Lymphoma. 2018 May;59(5):1213-1221. doi: 10.1080/10428194.2017.1365851. Epub 2017 Aug 25.
6
Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy.
Blood. 2016 Nov 24;128(21):2489-2496. doi: 10.1182/blood-2016-05-718528. Epub 2016 Aug 29.
7
Measures of follow-up in time-to-event studies: Why provide them and what should they be?
Clin Trials. 2015 Aug;12(4):403-8. doi: 10.1177/1740774515586176. Epub 2015 May 29.
Zotero 插件